Bayesian Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Bayesian Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,078	Closed	-$1.46M	–	1014
2023 Q3	$1.46M	Buy	+12,078	New	+$1.37M	0.17%	154
2022 Q4	–	Sell	-8,140	Closed	-$900K	–	1019
2022 Q3	$900K	Buy	+8,140	New	+$820K	0.18%	149
2022 Q2	–	Sell	-12,887	Closed	-$1.01M	–	1061
2022 Q1	$1.01M	Buy	+12,887	New	+$987K	0.15%	207
2021 Q2	–	Sell	-11,400	Closed	-$850K	–	630
2021 Q1	$850K	Buy	+11,400	New	+$1.05M	0.2%	141
2019 Q3	–	Sell	-2,900	Closed	-$441K	–	673
2019 Q2	$441K	Buy	+2,900	New	+$352K	0.09%	286
2018 Q3	–	Sell	-3,615	Closed	-$478K	–	781
2018 Q2	$478K	Buy	3,615 +634	+21%	+$59.8K	0.11%	275
2018 Q1	$221K	Buy	+2,981	New	+$199K	0.06%	473
2017 Q4	–	Sell	-18,200	Closed	-$826K	–	713
2017 Q3	$826K	Buy	18,200 +12,100	+198%	+$484K	0.2%	165
2017 Q2	$206K	Buy	+6,100	New	+$199K	0.08%	365

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bayesian Capital Management's SRPT Position: Q4 2023 in Review

Bayesian Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2023, closing a stake of 12,078 shares — an estimated $1.46M sold.

Bayesian Capital Management first reported a position in SRPT in Q2 2017 and held it in 9 quarters. The position peaked at $1.46M in Q3 2023. 395 funds tracked by Wall St. Rank hold SRPT as of Q4 2023.

Bayesian Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2023 after selling out during the quarter.
Bayesian Capital Management sold 12,078 Sarepta Therapeutics shares in Q4 2023, an estimated $1.46M.
Bayesian Capital Management first reported a position in Sarepta Therapeutics in Q2 2017 and held it in 9 quarters.
Bayesian Capital Management's Sarepta Therapeutics position peaked at $1.46M in Q3 2023.
395 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2023.

Based on Bayesian Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.